Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 273 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pediatric Brain Tumor Clear all

Conditions: Diffuse Intrinsic Pontine Glioma (DIPG), Brain Stem Glioma
Interventions: TTRNA-DC vaccines with GM-CSF, TTRNA-xALT, Cyclophosphamide + Fludarabine Lymphodepletive Conditioning, Dose-Intensified TMZ, Td vaccine, Autologous Hematopoietic Stem Cells (HSC); Biological · Drug
Lead sponsor: University of Florida; Other
Eligibility: 3 Years to 30 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Recurrent Childhood Brain Tumor
Interventions: Tumor biology testing, Temozolomide, Etoposide, Sorafenib, Everolimus, Erlotinib, Dasatinib; Device · Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 1 Month to 30 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Brain Tumor, Head and Neck Cancer
Interventions: substructure informed planning, Neurocognitive Testing, MRI; Radiation · Other · Diagnostic Test
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 1 Year to 26 Years
Enrollment: 338 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2035
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: Pediatric Brain Tumor
Interventions: Survivor's Journey+; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 15 Years to 25 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Cincinnati, Ohio • Columbus, Ohio

Conditions: Central Nervous System Tumor, Pediatric, Neuroblastoma
Interventions: temozolomide, thalidomide; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Up to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain and Central Nervous System Tumors, Metastatic Cancer
Interventions: verteporfin, conventional surgery; Drug · Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 3 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1994
U.S. locations: 2
States / cities: Milwaukee, Wisconsin

Conditions: Ependymoma, Ewing Sarcoma, High-grade Glioma, Leukemia and Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Neuroblastoma, Relapsed, Refractory Malignant Neoplasms, Rhabdomyosarcoma
Interventions: Nivolumab, NKTR-214; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Up to 30 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: Little Rock, Arkansas • St Louis, Missouri

Conditions: Brain Tumors, Non-CNS Malignancies
Interventions: Quality of Life surveys completed at specified timepoints; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 2 Years to 25 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain Tumor
Interventions: Cognitive training; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 7 Years to 16 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Brain Metastases, Adult, Primary Brain Tumor, Lung Cancer
Interventions: Noona® application; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Tumors, Central Nervous System
Interventions: Montanide; Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 21 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Central Nervous System Tumor, Pediatric
Interventions: Not listed
Lead sponsor: Pediatric Brain Tumor Consortium; Network
Eligibility: Up to 3 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more

Conditions: Brain Tumor, Central Nervous System Tumor
Interventions: filgrastim, carboplatin, cyclophosphamide, etoposide, vincristine sulfate, radiation therapy, Mesna, therapeutic conventional surgery; Biological · Drug · Radiation + 1 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2016
U.S. locations: 140
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 118 more

Conditions: Central Nervous System Neoplasms, Medulloblastoma
Interventions: Pomalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 1 Year to 21 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 6
States / cities: Stanford, California • Gainesville, Florida • Chicago, Illinois + 3 more

Conditions: Malignant Brain Glioma
Interventions: Magnetic Resonance Spectroscopic Imaging, Proton Therapy; Procedure · Device
Lead sponsor: Emory University; Other
Eligibility: Up to 21 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Oligodendroglioma
Interventions: lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis, pharmacological study, positron emission tomography, magnetic resonance imaging; Drug · Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
Interventions: filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation; Procedure · Biological · Drug
Lead sponsor: Indiana University; Other
Eligibility: 5 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 2
States / cities: Indianapolis, Indiana • Boston, Massachusetts

Conditions: Central Nervous System Sarcoma, Ependymoma, Glioma, Malignant Intracranial Germ Cell Tumor, Medulloblastoma, Pineoblastoma, Primary Central Nervous System Neoplasm
Interventions: Placebo Administration, Questionnaire Administration, Wound Dressing Material; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 2 Years to 17 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Childhood Brain Neoplasm, Recurrent Childhood Brain Neoplasm
Interventions: Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol Non-Stoichiometric Magnetite, Gadolinium; Procedure · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 5 Years to 18 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Recurrent Diffuse Pontine Gliomas
Interventions: nimotuzumab (anti EGFR humanized monoclonal antibody); Biological
Lead sponsor: YM BioSciences; Industry
Eligibility: 3 Years to 18 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 10
States / cities: Denver, Colorado • Washington D.C., District of Columbia • Gainesville, Florida + 6 more

Conditions: Wilms' Tumor, Sarcoma, Adenaocortical Carcinoma, Refractory Cancer, Coldrhood Cancer
Interventions: Tariquidar; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 2 Years to 18 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: High Grade Glioma, Ependymoma
Interventions: Optune NovoTTF-200A System; Device
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 5 Years to 21 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Orlando, Florida • Hackensack, New Jersey

Conditions: Leukemia, Lymphoma, Brain Tumor
Interventions: Education information system; Behavioral
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 10 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Sarcoma, Neuroblastoma, Wilms Tumor, Osteosarcoma, Brain Tumor
Interventions: Pazopanib (GW786034); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 25 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)

Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors

Cognitive Outcomes After Brain Substructure-informed Radiation Planning in Pediatric Patients

Survivors Journey+

Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma

Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors

A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer

Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies

Neuroplasticity-Based Cognitive Remediation for Pediatric Brain Tumor Survivors

Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy

Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors

Genetic Study of Brain Tumors in Young Children

Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors

Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors

Combination Chemotherapy Plus Gene Therapy in Treating Patients With CNS Tumors

StrataXRT in Preventing Radiation Dermatitis in Pediatric Patients Undergoing Radiation Therapy to the Brain or Spinal Cord

DSC-MRI With Ferumoxytol and DCE-MRI With Gadolinium in Imaging Vascular Properties in Younger Patients With Brain Tumors

Phase 2 Study of Nimotuzumab in Pediatric Recurrent Diffuse Intrinsic Pontine Glioma

Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors

HUMC 1612: Optune NovoTTF-200A System

A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors